Výsledky vyhledávání - "C. Wasserheit"

P1-17-08: A Phase II Trial of Ganetespib: Efficacy and Safety in Patients (pts) with Metastatic Breast Cancer (MBC)

Autor: ME Moynahan, C Wasserheit-Leiblich, Theresa Gilewski, Gabriella D'Andrea, S Chandarlapaty, Pamela Drullinsky, L Bauman, S. Patil, Steven Sugarman, Komal Jhaveri, D. Lake, V. Vukovic, Shanu Modi, Clifford A. Hudis, Sofia Haque, Iman El-Hariry

Publikováno v: Cancer Research. 71:P1-17

Background: Heat shock protein 90 (Hsp90) is a molecular chaperone that maintains the stability of a number of key cellular oncoproteins (client proteins). When Hsp90 is inhibited, its client proteins undergo ubiquitination and degradation. HER2 is o

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::89ba59d1ecdc85056eafc3c833080a69
https://doi.org/10.1158/0008-5472.sabcs11-p1-17-08

Zobrazit plný text záznamu

Radiosensitization of tumor-targeted radioimmunotherapy with prolonged topotecan infusion in human breast cancer xenografts

Autor: B, Ng, E, Kramer, L, Liebes, C, Wasserheit, H, Hochster, E, Blank, R, Ceriani, P, Furmanski

Publikováno v: Cancer research. 61(7)

Clinical radioimmunotherapy (RIT) of solid tumors holds great promise, but as yet has been unable to deliver tumoricidal radiation doses without unacceptable toxicity. Our experimental approach aims to potentiate the therapeutic action of radioimmuno

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::42faf33551ad5db115c86cce46b34807
https://pubmed.ncbi.nlm.nih.gov/11306478

Zobrazit plný text záznamu

Strategies for reduction of anthracycline cardiac toxicity

Autor: J, Speyer, C, Wasserheit

Publikováno v: Seminars in oncology. 25(5)

Anthracyclines are one of the most active classes of antineoplastic compounds. The limiting toxicity of this class of drugs is a cumulative, dose-related diffuse cardiomyopathy, which occurs in up to 20% of patients with a cumulative doxorubicin dose

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::cc38fb3db94f280e92fb3a0c8726c884
https://pubmed.ncbi.nlm.nih.gov/9783592

Zobrazit plný text záznamu

Initial clinical evaluation of radiolabeled MX-DTPA humanized BrE-3 antibody in patients with advanced breast cancer

Autor: E L, Kramer, L, Liebes, C, Wasserheit, M E, Noz, E W, Blank, A, Zabalegui, J, Melamed, P, Furmanski, J A, Peterson, R L, Ceriani

Publikováno v: Clinical cancer research : an official journal of the American Association for Cancer Research. 4(7)

To evaluate radiometal-labeled humanized BrE-3 (huBrE-3) monoclonal antibody as a radioimmunolocalization and therapeutic agent in breast cancer patients, tumor localization, pharmacokinetics, radiation dosimetry, and immunogenicity of (111)In-labele

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::bed8a63f16a388c0ea147c352a097f81
https://pubmed.ncbi.nlm.nih.gov/9676842

Zobrazit plný text záznamu

Taxanes in adjuvant and neoadjuvant therapies for breast cancer

Autor: J, O'Leary, M, Volm, C, Wasserheit, F, Muggia

Publikováno v: Oncology (Williston Park, N.Y.). 12(1 Suppl 1)

Paclitaxel (Taxol) is a diterpene originally obtained from the bark of the Pacific Yew Tree, Taxus Brevifolia. Its mechanism of action is unique. It stabilizes microtubule polymerization, thus blocking cells in the G2/M phase of the cell cycle. In br

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::4837835c66bf447fa128e0f1c7167e3d
https://pubmed.ncbi.nlm.nih.gov/9516599

Zobrazit plný text záznamu

Factors affecting the mobilization of primitive and committed hematopoietic progenitors into the peripheral blood of cancer patients

Autor: J G, Schneider, J P, Crown, C, Wasserheit, A, Kritz, G, Wong, L, Reich, L, Norton, M A, Moore

Publikováno v: Bone marrow transplantation. 14(6)

Rapid hematopoietic reconstitution following peripheral blood progenitor cell (PBPC) autotransplantation is thought to result from reinfusion of committed progenitor cells. This has raised concern that PBPC autografts might be rich in committed hemat

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::261dc2320c874df4a79eb3ed1dd523ed
https://pubmed.ncbi.nlm.nih.gov/7536069

Zobrazit plný text záznamu

Simultaneous dose escalation and schedule intensification of carboplatin-based chemotherapy using peripheral blood progenitor cells and filgrastim: a phase I trial

Autor: D, Fennelly, C, Wasserheit, J, Schneider, T, Hakes, L, Reich, J, Curtin, T J, Yao, M, Markman, L, Norton, J, Crown

Publikováno v: Cancer research. 54(23)

Our purpose was to determine the maximum tolerated dose of, and the minimum interval between treatments with, multiple cycles of carboplatin (CBDCA) rescued with peripheral blood progenitors and filgrastim. Eligible patients had advanced cancers with

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::2c08fc84f649c5ae6177d58f6944bb63
https://pubmed.ncbi.nlm.nih.gov/7525055

Zobrazit plný text záznamu

High-intensity chemotherapy with peripheral blood progenitor cell support

Autor: D, Fennelly, L, Vahdat, J, Schneider, L, Reich, N, Hamilton, T, Hakes, G, Raptis, C, Wasserheit, A, Kritz, S, Gulati

Publikováno v: Seminars in oncology. 21(2 Suppl 2)

In a series of clinical studies at Memorial Sloan-Kettering Cancer Center, we have used hematopoietic growth factors and peripheral blood-derived hematopoietic progenitor cells to facilitate delivery of multiple courses of high-dose chemotherapy at a

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::e415a6ee9633fb196b4d6c85f5003af2
https://pubmed.ncbi.nlm.nih.gov/7515513

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání